从偶联位点、偶联剂、载体蛋白和偶联步骤等分析出发,设计了微囊藻毒素-LR (Microcystin- LR ,MC- LR)完全抗原的制备方法.在半抗原分子第7位氨基酸分子上引进1个自由的氨基;再用戊二醛2步法将此中间产物(H2 N etMC- LR)分别与BSA和OVA...从偶联位点、偶联剂、载体蛋白和偶联步骤等分析出发,设计了微囊藻毒素-LR (Microcystin- LR ,MC- LR)完全抗原的制备方法.在半抗原分子第7位氨基酸分子上引进1个自由的氨基;再用戊二醛2步法将此中间产物(H2 N etMC- LR)分别与BSA和OVA偶联.中间产物和偶联产物分别经固相萃取和透析纯化后,经SDS凝胶电泳、紫外扫描及生物质谱技术鉴定,结果表明MC- LR与BSA的平均偶联比能达到5以上,满足了进一步免疫的要求.展开更多
目的:合成玉米赤霉烯酮(ZEN)半抗原及全抗原,并鉴定其是否合成成功,为制备ZEN抗体奠定基础。方法:将ZEN与羧甲氧基胺半盐酸盐(O-(carboxym ethyl)hydroxyla-m ine hem ihydrochloride)反应,合成半抗原ZEN-6-羧甲氧基胺(ZEN-oxim e),采用...目的:合成玉米赤霉烯酮(ZEN)半抗原及全抗原,并鉴定其是否合成成功,为制备ZEN抗体奠定基础。方法:将ZEN与羧甲氧基胺半盐酸盐(O-(carboxym ethyl)hydroxyla-m ine hem ihydrochloride)反应,合成半抗原ZEN-6-羧甲氧基胺(ZEN-oxim e),采用TLC、HPLC和液相-质谱联用技术进行半抗原的纯化、鉴定;通过活泼酯法将半抗原与载体蛋白偶联制备ZEN全抗原,采用紫外光谱法、TNBS法结合比的测定以及免疫学方法进行全抗原鉴定。结果:鉴定结果表明目标半抗原及全抗原合成成功。结论:本研究采用多种方法进行半抗原及全抗原的鉴定,结果皆表明目标半抗原及全抗原合成成功,说明本研究合成ZEN半抗原及人工抗原的技术路线是可行的,为进一步研制ZEN的抗体奠定良好基础。展开更多
BACKGROUND Colorectal cancer is currently the third most common malignant tumor and the second leading cause of cancer-related death worldwide.Neoadjuvant chemoradiotherapy(nCRT)is standard for locally advanced rectal...BACKGROUND Colorectal cancer is currently the third most common malignant tumor and the second leading cause of cancer-related death worldwide.Neoadjuvant chemoradiotherapy(nCRT)is standard for locally advanced rectal cancer(LARC).Except for pathological examination after resection,it is not known exactly whether LARC patients have achieved pathological complete response(pCR)before surgery.To date,there are no clear clinical indicators that can predict the efficacy of nCRT and patient outcomes.AIM To investigate the indicators that can predict pCR and long-term outcomes following nCRT in patients with LARC.METHODS Clinical data of 128 LARC patients admitted to our hospital between September 2013 and November 2022 were retrospectively analyzed.Patients were categorized into pCR and non-pCR groups.Univariate analysis(using the χ^(2) test or Fisher’s exact test)and logistic multivariate regression analysis were used to study clinical predictors affecting pCR.The 5-year disease-free survival(DFS)and overall survival(OS)rates were calculated using Kaplan-Meier analysis,and differences in survival curves were assessed with the log-rank test.RESULTS Univariate analysis showed that pretreatment carcinoembryonic antigen(CEA)level,lymphocyte-monocyte ratio(LMR),time interval between neoadjuvant therapy completion and total mesorectal excision,and tumor size were correlated with pCR.Multivariate results showed that CEA≤5 ng/mL(P=0.039),LMR>2.73(P=0.023),and time interval>10 wk(P=0.039)were independent predictors for pCR.Survival analysis demonstrated that patients in the pCR group had significantly higher 5-year DFS rates(94.7%vs 59.7%,P=0.002)and 5-year OS rates(95.8%vs 80.1%,P=0.019)compared to the non-pCR group.Tumor deposits(TDs)were significantly correlated with shorter DFS(P=0.002)and OS(P<0.001).CONCLUSION Pretreatment CEA,LMR,and time interval contribute to predicting nCRT efficacy in LARC patients.Achieving pCR demonstrates longer DFS and OS.TDs correlate with poor prognosis.展开更多
文摘从偶联位点、偶联剂、载体蛋白和偶联步骤等分析出发,设计了微囊藻毒素-LR (Microcystin- LR ,MC- LR)完全抗原的制备方法.在半抗原分子第7位氨基酸分子上引进1个自由的氨基;再用戊二醛2步法将此中间产物(H2 N etMC- LR)分别与BSA和OVA偶联.中间产物和偶联产物分别经固相萃取和透析纯化后,经SDS凝胶电泳、紫外扫描及生物质谱技术鉴定,结果表明MC- LR与BSA的平均偶联比能达到5以上,满足了进一步免疫的要求.
文摘目的:合成玉米赤霉烯酮(ZEN)半抗原及全抗原,并鉴定其是否合成成功,为制备ZEN抗体奠定基础。方法:将ZEN与羧甲氧基胺半盐酸盐(O-(carboxym ethyl)hydroxyla-m ine hem ihydrochloride)反应,合成半抗原ZEN-6-羧甲氧基胺(ZEN-oxim e),采用TLC、HPLC和液相-质谱联用技术进行半抗原的纯化、鉴定;通过活泼酯法将半抗原与载体蛋白偶联制备ZEN全抗原,采用紫外光谱法、TNBS法结合比的测定以及免疫学方法进行全抗原鉴定。结果:鉴定结果表明目标半抗原及全抗原合成成功。结论:本研究采用多种方法进行半抗原及全抗原的鉴定,结果皆表明目标半抗原及全抗原合成成功,说明本研究合成ZEN半抗原及人工抗原的技术路线是可行的,为进一步研制ZEN的抗体奠定良好基础。
基金Supported by the National Natural Science Foundation of China,No.82073476the National Key R&D Program of China,No.2022YFC2503700 and No.2022YFC2503703+1 种基金Jiangsu Provincial Medical Key Discipline,No.ZDXK202235Innovation Research Project of Medical and Industrial Cooperation in Suzhou,No.SLJ2021005.
文摘BACKGROUND Colorectal cancer is currently the third most common malignant tumor and the second leading cause of cancer-related death worldwide.Neoadjuvant chemoradiotherapy(nCRT)is standard for locally advanced rectal cancer(LARC).Except for pathological examination after resection,it is not known exactly whether LARC patients have achieved pathological complete response(pCR)before surgery.To date,there are no clear clinical indicators that can predict the efficacy of nCRT and patient outcomes.AIM To investigate the indicators that can predict pCR and long-term outcomes following nCRT in patients with LARC.METHODS Clinical data of 128 LARC patients admitted to our hospital between September 2013 and November 2022 were retrospectively analyzed.Patients were categorized into pCR and non-pCR groups.Univariate analysis(using the χ^(2) test or Fisher’s exact test)and logistic multivariate regression analysis were used to study clinical predictors affecting pCR.The 5-year disease-free survival(DFS)and overall survival(OS)rates were calculated using Kaplan-Meier analysis,and differences in survival curves were assessed with the log-rank test.RESULTS Univariate analysis showed that pretreatment carcinoembryonic antigen(CEA)level,lymphocyte-monocyte ratio(LMR),time interval between neoadjuvant therapy completion and total mesorectal excision,and tumor size were correlated with pCR.Multivariate results showed that CEA≤5 ng/mL(P=0.039),LMR>2.73(P=0.023),and time interval>10 wk(P=0.039)were independent predictors for pCR.Survival analysis demonstrated that patients in the pCR group had significantly higher 5-year DFS rates(94.7%vs 59.7%,P=0.002)and 5-year OS rates(95.8%vs 80.1%,P=0.019)compared to the non-pCR group.Tumor deposits(TDs)were significantly correlated with shorter DFS(P=0.002)and OS(P<0.001).CONCLUSION Pretreatment CEA,LMR,and time interval contribute to predicting nCRT efficacy in LARC patients.Achieving pCR demonstrates longer DFS and OS.TDs correlate with poor prognosis.
